David M. Charytan
New York University
224 Papers
1.1K Citations
David M. Charytan is an academic researcher from New York University. The author has contributed to research in topics: Medicine & Kidney disease. The author has an hindex of 41, co-authored 150 publications. Previous affiliations of David M. Charytan include Brigham and Women's Hospital & Harvard University.
Chat about Author
Papers
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic,Vlado Perkovic,Meg Jardine,Meg Jardine,Bruce Neal,Bruce Neal,Bruce Neal,Severine Bompoint,Hiddo J.L. Heerspink,David M. Charytan,David M. Charytan,Robert Edwards,Rajiv Agarwal,Rajiv Agarwal,George L. Bakris,Scott Bull,Christopher P. Cannon,Christopher P. Cannon,George Capuano,Pei-Ling Chu,Dick de Zeeuw,Tom Greene,Adeera Levin,Carol A. Pollock,David C. Wheeler,Yshai Yavin,Hong Zhang,Bernard Zinman,Gary Meininger,Barry M. Brenner,Kenneth W. Mahaffey +30 more
TL;DR: In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years.
4.9K
BMP-7 counteracts TGF-β1–induced epithelial-to-mesenchymal transition and reverses chronic renal injury
Michael Zeisberg,Jun-ichi Hanai,Hikaru Sugimoto,Tadanori Mammoto,David M. Charytan,Frank Strutz,Raghu Kalluri +6 more
TL;DR: It is reported that BMP-7 reverses TGF-β1–induced epithelial-to-mesenchymal transition (EMT) by reinduction of E-cadherin, a key epithelial cell adhesion molecule, which provides evidence of cross talk between B MP-7 and TGF -β1 in the regulation of EMT in health and disease.
1.4K
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
Brendon L. Neuen,Tamara Young,Hiddo J.L. Heerspink,Hiddo J.L. Heerspink,Bruce Neal,Bruce Neal,Bruce Neal,Vlado Perkovic,Laurent Billot,Kenneth W. Mahaffey,David M. Charytan,David C. Wheeler,Clare Arnott,Clare Arnott,Clare Arnott,Severine Bompoint,Adeera Levin,Meg Jardine +17 more
TL;DR: Evidence is provided that the proportional effect of SGLT2 inhibitors might attenuate with declining kidney function and there was clear, separate evidence of benefit for all eG FR subgroups, including for participants with a baseline eGFR 30-45 mL/min per 1·73 m2.
761
Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
Charles A. Herzog,Charles A. Herzog,Richard W. Asinger,Richard W. Asinger,Alan K. Berger,David M. Charytan,Javier Díez,Robert G. Hart,Kai-Uwe Eckardt,Bertram L. Kasiske,Bertram L. Kasiske,Peter A. McCullough,Rod S. Passman,Stephanie DeLoach,Patrick H. Pun,Eberhard Ritz +15 more
TL;DR: The current state of knowledge and the implications for patient care in important topic areas, including coronary artery disease and myocardial infarction, congestive heart failure, cerebrovascular disease, atrial fibrillation, peripheral arterial disease, and sudden cardiac death are defined.
693
Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series.
Amy Rapkiewicz,Xingchen Mai,Steven E. Carsons,Stefania Pittaluga,David E. Kleiner,Jeffrey S. Berger,Sarun Thomas,Nicole Adler,David M. Charytan,Billel Gasmi,Judith S. Hochman,Harmony R. Reynolds +11 more
TL;DR: In this series of seven COVID-19 autopsies, thrombosis was a prominent feature in multiple organs, in some cases despite full anticoagulation and regardless of timing of the disease course, suggesting that thROMbosis plays a role very early in the disease process.
558